Skip to main content
VCbacked
Log inGet Started

ThirdLaw Molecular

Blue Bell, United States

ThirdLaw Molecular pioneers revolutionary SpiroligomerN molecules for safer, more targeted, effective disease treatment.

$1.5M raised
Feb 2025
Pre-Seed
BiotechnologyHealth DiagnosticsLife ScienceTherapeutics

Top Investors

SmartGateVCDefense Threat Reduction Agency (DTRA)Bowman's Tower Venture Partners

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about ThirdLaw Molecular

How much funding has ThirdLaw Molecular raised?
ThirdLaw Molecular has raised $1.5M in total funding. The most recent round was Pre-Seed. The last funding was announced in February 2025.
Who are ThirdLaw Molecular's investors?
ThirdLaw Molecular's investors include SmartGateVC, Defense Threat Reduction Agency (DTRA), Bowman's Tower Venture Partners.
Where is ThirdLaw Molecular headquartered?
ThirdLaw Molecular is headquartered in Blue Bell, United States.
What does ThirdLaw Molecular do?
ThirdLaw Molecular pioneers revolutionary SpiroligomerN molecules for safer, more targeted, effective disease treatment.
What stage is ThirdLaw Molecular at?
ThirdLaw Molecular is at the Pre-Seed stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"ThirdLaw Molecular — Funding & Investors." VCBacked, February 13, 2025, https://www.vcbacked.co/company/thirdlaw-molecular. Accessed June 17, 2026.
APA
VCBacked. (2025). ThirdLaw Molecular — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/thirdlaw-molecular
Wikipedia (cite web)
{{cite web |title=ThirdLaw Molecular — Funding & Investors |url=https://www.vcbacked.co/company/thirdlaw-molecular |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong